Nevro Corp Completes Enrollment of U.S. Randomized Pivotal Trial of Novel Chronic Pain Treatment

MENLO PARK, Calif.--(BUSINESS WIRE)--Nevro Corp., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, today announced completion of enrollment in the SENZA-RCT U.S. pivotal study, designed as the largest prospective, randomized, controlled pivotal study in spinal cord stimulation (SCS) to date. The SENZA RCT study is intended to evaluate the safety and efficacy of the Nevro® Senza® High-Frequency Spinal Cord Stimulation (HF-SCS) System in patients with chronic, intractable pain of the back and legs. The study enrolled 241 patients over a seven-month period at 11 leading pain centers across the U.S. Patients were randomized to receive either the Senza HF- SCS system or a traditional low-frequency SCS system.